HeartFlowHTFL -4.43%12 EV-to-EBIT is -20.80 as of Jul. 08, 2026. GuruFocus rates HTFL with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 468 Healthcare Providers & Services companies, HeartFlow ranks worse than 213675% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
HeartFlow's Enterprise Value for the quarter that ended in Mar. 2026 was $1,963.0 Mil.
HeartFlow's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-101.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeartFlow EV-to-EBIT Related Terms
HeartFlow EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for HeartFlow's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, HeartFlow's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeartFlow EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HeartFlow's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where HeartFlow's EV-to-EBIT falls into.
HeartFlow's current Enterprise Value is $2,117.2 Mil.
HeartFlow's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-101.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeartFlow (HTFL) has a EV-to-EBIT of -20.80 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on HeartFlow and its competitors. According to the industry distribution chart, HeartFlow ranks #999999 out of 468 companies in the Healthcare Providers & Services industry.
Is HeartFlow's EV-to-EBIT too high?
HeartFlow's current EV-to-EBIT is -20.80. Based on the distribution chart, HeartFlow ranks #999999 out of 468 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, HeartFlow has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does HeartFlow's EV-to-EBIT compare to PRVA and WAY?
According to the Healthcare Providers & Services industry distribution chart, HeartFlow ranks #999999 out of 468 companies for EV-to-EBIT. This places HeartFlow in the lower half of its industry. The industry median EV-to-EBIT is 15.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.97, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on HeartFlow and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeartFlow's current EV-to-EBIT is -20.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartFlow stock overvalued right now?
HeartFlow (HTFL) has a current EV-to-EBIT of -20.80. The current EV-to-EBIT is -20.80. HeartFlow's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For HeartFlow (HTFL), the current EV-to-EBIT is -20.80 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
12GF Score
Get the complete analysis for HTFL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTFL has been successfully added to your 
